Rexahn, a clinical stage biopharmaceutical company developing oncology and CNS therapeutics, has completed patient enrollment in its phase-IIa clinical trial. The study is to evaluate the effectiveness of Serdaxin as a treatment for major depressive disorder (MDD).
The Serdaxin study for MDD was initiated in February 2009, with preliminary findings anticipated in late 2009. The primary efficacy endpoint of the Serdaxin phase IIa is the change from baseline on the Montgomery-Asberg Depression Rating Scale.
Chang Ahn, Chief Executive Officer of Rexahn, said: “The completion of patient enrollment in the Phase IIa clinical trial moves us closer to bringing Serdaxin to market as quickly as possible. For the many patients suffering from MDD, Serdaxin holds the promise of being an effective treatment without producing the serious side effects commonly associated with currently marketed antidepressant drugs.